Table 2. Effects of treatment with trans-ferulic acid derivatives on the levels of cancer hallmark markers in cell lysate from HepG2 cells treated with the selected compounds at their IC50.
| Codes | Parameter | ||||||
|---|---|---|---|---|---|---|---|
| AFP (ng mL−1) | BCL-2 (ng mL−1) | Caspase-3 (ng mL−1) | MCL-1 (pg mL−1) | P53 (pg mL−1) | Urokinase (ng mL−1) | DCP (ng mL−1) | |
| 4a | 1756 | 10.6 | 257 | 646 | 547 | 2302 | 0.96 |
| (±8) | (±0.4) | (±9) | (±13) | (±11) | (±36) | (±0.06) | |
| 4d | 1880 | 6.3 | 236 | 400 | 434 | 1753 | 0.68 |
| (±16) | (±0.15) | (±17) | (±13) | (±22) | (±18) | (±0.07) | |
| 4e | 921 | 3.3 | 469 | 206 | 1018 | 952 | 0.17 |
| (±15) | (±0.2) | (±11) | (±10) | (±19) | (±29) | (±0.01) | |
| 12 | 998 | 3.53 | 413 | 229 | 722 | 1002 | 0.61 |
| (±17) | (±0.4) | (±15) | (±8) | (±11) | (±19) | (±0.03) | |
| DMSO a | 3545 | 15.0 | 131 | 943 | 246 | 3847 | 1.64 |
| (±24) | (±0.5) | (±15) | (±29) | (±14) | (±34) | (±0.10) | |
| DOX b | 612 | 2.69 | 599 | 153 | 1282 | 709 | 0.25 |
| (±12) | (±0.45) | (±17) | (±9) | (±16) | (±27) | (±0.04) | |
| TFA | 1459 | 4.67 | 282 | 345 | 556 | 1585 | 0.29 |
| (±20) | (±0.4) | (±16) | (±9) | (±13) | (±34) | (±0.02) | |
a
Difference from non-treated HepG2 cells (negative control).
b
Difference from doxorubicin-treated HepG2 cells (positive control).